Medical therapy of Graves' disease: Effect on remission rates of methimazole alone and in combination with triiodothyronine

European Journal of Endocrinology

Volumn 142, Issue 2, 2000, Pages 117-124

  Raber, Wolfgang ^a,b   Kmen, Elisabeth ^a   Waldhäusl, Werner ^a   Vierhapper, Heinrich ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Div of Endocrinology and Metabolism   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; PROPRANOLOL; THIAMAZOLE; THYROID HORMONE; THYROTROPIN RECEPTOR ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GRAVES DISEASE; HEART PALPITATION; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0034005713     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1420117     Document Type: Article

References (43)

1. McKenzie JM & Zakarija M. Hyperthyroidism. In Endocrinology, edn 3, pp 676-711. Ed. LJ DeGroot. Philadelphia: WB Saunders, 1995.
2. Wartofsky L, Glinoer D, Solomon S, Nagataki R & Lagasse R. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe. Japan and the United States. Thyroid 1991 1 129-135.
3. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J & Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. New England Journal of Medicine 1998 338 712-718.
4. Bartalena L, Marocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine 1998 338 73-78.
5. Medley AJ, Young SJ, Jones SJ, Alexander WD & Bewsher PD. Scottish automated follow-up register group. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long term follow-up of 434 patients. Clinical Endocrinology 1989 31 209-218.
6. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kohayashi K et al. Administration of thyroxine in treated Graves' disease - effects on the level of antibodies to thyroid-stimulating hormone receptor and on the risk of recurrence of hyperthyroidism. New England Journal of Medicine 1991 324 947-953.
7. Hashizume K, Ichikawa K, Nishii Y, Kobayashi M, Sakurai A, Miyamoto T et al. Effect of administration of thyroxine on the risk of postpartum recurrence of Graves' disease. Journal of Clinical Endocrinology and Metabolism 1992 75 6-10.
8. Hashizume K & DeGroot LJ. Release of thyrotropin receptor from thyroid plasma membranes: effect of hydrocortisone, propranolol, and adenosine 3′,5′-monophosphate. Endocrinology 1980 106 1465-1468.
9. Sakurai A, Nakai A & DeGroot LJ. Expression of three forms of thyroid hormone receptor in human tissues. Molecular Endocrinology 1989 3 392-399.
10. Edmonds CJ & Tellez M. Treatment of Graves' disease by carbimazole: high dose with T4 compared with titration dose. European Journal of Endocrinology 1994 131 120-124.
11. Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. Journal of Clinical Endocrinology and Metabolism 1991 80 1481-1484.
12. McIver B, Rae P, Becket G, Wilkinson E, Gold A & Toft A. Lack of effect of T4 in patients with Graves' hyperthyroidism who are treated with antithyroid drugs. New England Journal of Medicine 1996 334 220-224.
13. Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M et al. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? Journal of Clinical Endocrinology and Metabolism 1997 82 2410-2413.
14. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. Journal of Clinical Endocrinology and Metabolism 1998 83 814-818.
15. Pfeilschifter J & Ziegler R. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume. European Journal of Endocrinology 1997 136 81-86.
16. Wartofsky L. Low remission rates after therapy for Graves' disease: possible relation of dietary iodine with antithyroid therapy results. Journal of the American Medical Association 1977 226 1083-1088.
17. Azizi F. Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter. Journal of Clinical Endocrinology and Metabolism 1985 61 374-377.
18. Alexander WD, Harden RM, Koutras DA & Wayne E. Influence of iodine intake after antithyroid drug treatment. Lancet 1965 2 866-868.
19. Werner SC. Modification of the classilication of the eye changes in Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. Journal of Clinical Endocrinology and Metabolism 1977 44 203.
20. Gutekunst R, Becker W, Hehrmann R, Olbricht TH & Pfannenstiel P. Utraschalldiagnostik der Schilddrüse. Deutsche Medizinische Wochenschrift 1988 113 1109-1112.
21. Lorenz-Wawschinek O, Tiran B, Eber O & Langsteger W. Photometric determination of iodine in urine. Experimental and Clinical Endocrinology 1994 102 57-58.
22. Gutekunst R, Smolarek H, Hasenpusch U, Stubbe P, Friedrich HJ, Wood WG et al. Goitre epidemiology: thyroid volume, iodine excretion, thyroglobulin and thyrotropin in Germany and Sweden. Acta Endocrinologica 1986 112 494-501.
23. Solomon DH, Beck JC, Van der Laan WP & Astwood EB. Prognosis of hyperthyroidism treated by antithyroid drugs. Journal of the American Medical Association 1953 152 201-205.
24. Sugrue D, McEvoy M, Feely J & Drury MI. Hyperthyroidism in the land of Graves: results of treatment by surgery, radio-iodine and carbimazole in 837 cases. Quarterly Journal of Medicine 1980 49 51-61.
25. Cooper DS. Antithyroid drugs. New England Journal of Medicine 1984 311 1353-1362.
26. Kahaly G, Dienes HP, Beyer J & Hommel G. Randomized, double blind, placebo-controlled trial of low dose iodine in endemic goiter. Journal of Clinical Endocrinology and Metabolism 1997 82 4049-4053.
27. Allanic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. Journal of Clinical Endocrinology and Metabolism 1990 70 675-679.
28. Wilson R, Buchanan L, Fraser WD, McKillop JH & Thomson JA. Do higher doses of carbimazole improve remission in Graves' disease? Quarterly Journal of Medicine 1996 89 381-385.
29. Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Wener MC et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1983 57 563-570.
30. Weetman AP, McGregor AM & Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clinical Endocrinology 1984 21 163-172.
31. Paschke R, Vogg M, Kristoferitsch R, Aktuna D, Wawschinek O, Eber O et al. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. Journal of Clinical Endocrinology and Metabolism 1995 80 2470-2474.
32. Greer M, Kammer H & Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves' disease. New England Journal of Medicine 1977 297 173-176.
33. MacFarlane IA, Davies D, Longson D, Shalet SM & Beardwell CG. Single daily dose short-term carbimazole therapy for hyperthyroid Graves' disease. Clinical Endocrinology 1983 18 557-561.
34. Reinwein D, Benker G, Lazarus JH & Alexander WD. European multicenter group on antithyroid drug treatment: a prospective randomized trial of antithyroid drug dose in Graves' disease therapy. Journal of Clinical Endocrinology and Metabolism 1993 76 1516-1521.
35. Ladenson PW. Treatment for Graves' disease: letting the thyroid rest (editorial). New England Journal of Medicine 1991 324 989-990.
36. Wiersinga WM. Immunosuppression of Graves' hyperthyroidism -still an elusive goal (editorial). New England Journal of Medicine 1996 334 265-266.
37. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R & Carayon P. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. Journal of Clinical Endocrinology and Metabolism 1988 67 656-662.
38. Dawson-Saunders B & Trapp RG. Basic and Clinical Biostatistics, edn 2. Norwalk: Appleton & Lange, 1994.
39. Singer PA. Will postpartum recurrence of Graves' hyperthyroidism become a thing of the past? (editorial). Journal of Clinical Endocrinology and Metabolism 1992 75 5A-6A.
40. Buchinger W, Lorenz-Wawschinek L, Semlitsch G, Langsteger W, Binter G, Bonelli R et al. Thyrotropin and thyroglobulin as an index of optimal iodine intake: correlation with iodine excretion of 39 913 euthyroid patients. Thyroid 1997 7 592-597.
41. Braverman LE. Is there one successful antithyroid regimen for Graves' disease? (editorial). Lancet 1996 348 697-698.
42. Reinwein D, Benker G, König MP, Pinchera A, Schatz H & Schleusener H. Klinische Aspekte der Hyperthyreose in Gebieten unterschiedlicher Jodversorgung. Ergebnisse einer europäischen prospektiven Studie. Schweizer Medizinische Wochenschrift 1987 117 1245-1255.
43. Ishizuki Y, Ishizuki Y, Hirooka Y & Murata Y. Urinary iodine excretion in Japanese people and thyroid dysfunction. Nippon Naipumpi Gakkai Zasshi 1992 68 550-556. (Abstract in English)